Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
PUBLISHED 6:42 PM EDT Aug. 24, 2022Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday
People between the ages of 40 and 65 saw no measurable benefit, according to the analysis of medical records; a spokesman for Pfizer declined to comment on the results published in the New England Journal of MedicineThe results from a 109,000-patient Israeli study are likely to renew questions about the U.S. government’s use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience.
The study has limitations due to its design, which compiled data from a large Israeli health system rather than enrolling patients in a randomized study with a control group — the gold-standard for medical research. A spokesman for Pfizer declined to comment on the results, which were published in the New England Journal of Medicine. late last year for adults and children 12 and older who are considered high risk due to conditions like obesity, diabetes and heart disease. More than 42% of U.S. adults are considered obese, representing 138 million Americans, according to the CDC.
“Those people do exist but they’re relatively rare because most people now have either gotten vaccinated or they’ve gotten infected,” Boulware said.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults.
Read more »
Pfizer COVID shots appear 73% effective in children under 5Pfizer’s COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring, the company announced Tuesday.
Read more »
Pfizer COVID shots appear 73% effective in children under 5Pfizer’s says its COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring.
Read more »
Pfizer touts effectiveness of COVID-19 shot in younger childrenPfizer says its three-dose COVID-19 vaccine for children 6 months through 4 years of age is 73.2% effective.
Read more »
COVID Antivirals Like Paxlovid ‘Vastly Underused' During Pandemic, Study SaysDespite clinical trials showing that it could significantly reduce the risk of death in COVID patients, studies have shown that antivirals like Paxlovid are being “vastly underused” during the pandemic.
Read more »